Australia markets closed

Gentherm Incorporated (THRM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.46-0.93 (-2.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.39
Open43.78
Bid42.70 x 900
Ask42.74 x 800
Day's range42.30 - 44.08
52-week range27.24 - 49.95
Volume480,665
Avg. volume141,179
Market cap1.449B
Beta (5Y monthly)1.43
PE ratio (TTM)49.78
EPS (TTM)0.85
Earnings date27 Oct 2020 - 02 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est44.67
  • GlobeNewswire

    Gentherm to Participate in Virtual CL King’s 18th Annual Best Ideas Conference

    NORTHVILLE, Mich., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), a global market leader and developer of innovative thermal management technologies, today announced that Phil Eyler, President and CEO, will participate in a virtual fireside chat at the CL King’s 18th Annual Best Ideas Conference on Wednesday, September 16, 2020. The presentation will begin at 9:30 am (ET). There will be a live audio webcast of the presentation and a replay will be available for 45 days following the presentation on the Events page of the Investor Relations section of Gentherm’s website at: www.gentherm.com.  Investor Contact Yijing Brentano investors@gentherm.com  248.308.1702Media Contact Melissa Fischer media@gentherm.com  248.289.9702About Gentherm Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, South Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam.  For more information, go to www.gentherm.com.

  • Gentherm (THRM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Gentherm (THRM) Reports Q2 Loss, Tops Revenue Estimates

    Gentherm (THRM) delivered earnings and revenue surprises of 44.44% and 17.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Gentherm Reports 2020 Second Quarter Results

    Reduced Operating Expenses by 30% from the Prior-year Period Strong Cash Flow Generation in the First Half of 2020 Despite Unprecedented Market Challenges  Total Liquidity of $369 Million at Quarter EndNORTHVILLE, Mich., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management technologies, today announced its financial results for the second quarter ended June 30, 2020.Second Quarter Highlights * Product revenues of $136.1 million decreased 44.1% from $243.3 million in the 2019 second quarter * Excluding the impact of foreign currency translation and divested assets, product revenues decreased 42.3% year over year * GAAP diluted loss per share was $0.32 compared to diluted earnings per share of $0.08 for the prior-year period * Adjusted loss per share (see table herein) was $0.30. Adjusted earnings per share in the prior-year period was $0.47 * Secured automotive new business awards totaling $300 millionPhil Eyler, Gentherm's President and CEO, said “I am proud of the team for their strong execution in the second quarter despite the unprecedented uncertainties created by the worldwide COVID-19 pandemic. While the Company’s revenue performance reflects the challenges in the underlying markets, our ongoing disciplined approach to managing expenses allowed us to reduce operating expense by 30% from a year ago.  In Medical, we delivered double-digit revenue growth both year over year and sequentially. Importantly, we generated a 24% increase in cash flow from operations in the first half of 2020 versus the prior-year period.“While the COVID-19 pandemic will continue to create challenges and uncertainties in the near term, the momentum we are seeing in new awards, winning the coveted General Motors Supplier of the Year award, coupled with aggressive cost management and our strong balance sheet position us well to continue to deliver over the long term,” continued Eyler.2020 Second Quarter Financial ReviewProduct revenues for the second quarter of 2020 of $136.1 million declined $107.3 million, or 44.1%, as compared to the prior-year period. Excluding the impact of foreign currency translation and divested assets, product revenues declined 42.3% year over year.Automotive revenues declined 45.8% year over year. All product categories saw revenue declines except Electronics. Adjusting for foreign currency translation, organic Automotive revenues decreased 44.9% year over year.  According to IHS Markit, actual light vehicle production declined by approximately 38.9% when compared to the second quarter of 2019 in the Company’s key markets of North America, Europe, China, Japan and Korea.The 14.3% revenue decrease in Industrial resulted from the divestiture of Global Power Technologies (“GPT”), which was sold on October 1, 2019. The decrease was partially offset by year-over-year growth of 18.2% in Gentherm Medical, primarily due to increased demand for our Blanketrol® solutions, including the support of temperature management for COVID-19 patients.See the “Revenue by Product Category” table included below for additional detail.The gross margin rate decreased to 19.6% in the current-year period, compared with 29.9% in the prior-year period, primarily as a result of lower Automotive volume due to the COVID-19 pandemic and annual customer price reductions.  These were partially offset by supplier cost reductions and positive sales mix as a result of the strength in our Medical business.Net research and development (R&D) expenses of $15.3 million in the 2020 second quarter decreased $3.9 million, or 20.3%, year over year as a direct result of cost reduction initiatives and lower incentive compensation.Selling, general and administrative (SG&A) expenses of $21.9 million in the 2020 second quarter decreased $10.3 million, or 32.0%, versus the prior-year period. The year-over-year decline was primarily driven by the impact of cost reduction initiatives, lower incentive compensation and the divestiture of the GPT business.During the quarter, the Company reduced its restructuring expenses by a net $0.6 million, primarily as a result of proactively reducing cash restructuring costs associated with previously announced plan to improve the Company’s manufacturing productivity and rationalize its footprint.As described more fully in the table included below, “Reconciliation of Net (Loss) Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $0.1 million during the second quarter of 2020 compared to $32.2 million in the prior year.Income tax expense in the 2020 second quarter was $0.2 million, as compared with $5.5 million in the prior-year period. The tax amount in 2020 included the effect of the settlement and closure of multi-year international tax audits of $3.4 million. Adjusted for the audit settlement impacts, the effective tax rate was 31.4%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.GAAP diluted loss per share for the second quarter of 2020 was $0.32 compared with diluted earnings per share of $0.08 for the prior-year period. Adjusted diluted loss per share, excluding restructuring expenses, income from sale of patents, unrealized currency gain, and other impacts (see table herein), was $0.30. Adjusted diluted earnings per share in the prior-year period was $0.47.As a result of the unprecedented uncertainty facing the automotive industry and global economy, Gentherm withdrew its 2020 guidance on March 25, 2020 and is not providing an update at this time. However, the Company expects product revenues in the third quarter of 2020 to improve sequentially to be in the range of $210 to $240 million.Conference CallAs previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-855-327-6837 (callers in the U.S.) or +1-631-891-4304 (callers outside this U.S.). The passcode for the live call is 10010358.A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.A telephonic replay will be available approximately 2 hours after the call until 11:59 pm Eastern Time on August 18, 2020. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 10010358.Investor Relations Contact Yijing Brentano investors@gentherm.com (248) 308-1702Media Contact Melissa Fischer media@gentherm.com 248.289.9702About GenthermGentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.Forward-Looking StatementsExcept for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements, including that: COVID-19 and its direct and indirect adverse impacts on the automobile and medical industries and global economy has, and will continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations and stock price; future borrowing availability under the Company’s revolving credit facility is subject to compliance with covenants thereunder, and the deterioration of the Company’s financial performance (including consolidated EBITDA) due to the COVID-19 has caused the borrowing availability to be, and it may continue to be for at least the next 12 months, substantially less than the full amount of revolving credit facility; the Company’s failure to be in compliance with covenants under the revolving credit facility due to COVID-19 or otherwise could result in an event of default thereunder, and if the lenders thereunder do not agree to amend or waive, the amounts outstanding under the revolving credit facility may be accelerated and may become immediately due and payable; additional financing by accessing the capital markets may not be available on acceptable terms, if at all, due to the impact of COVID-19 and additional indebtedness may harm the Company’s financial position and impact the Company’s ability to comply with covenants under the Company’s revolving credit facility; the Company may not realize the expected benefits from any restructuring initiatives it may pursue as a result of the effects of COVID-19 or otherwise; declines in automobile production may have an adverse impact; sales may not increase and the projected future sales volumes on which the Company manages its business may be inaccurate; new business awards may not be converted into product revenues and our projections thereof are not updated after the date initially communicated to us by customers, including for the impact of COVID-19 on future business; new or improved competing products may be developed by competitors with greater resources; customer preferences may shift, including due to the evolving use of automobiles and technology; the Company may lose suppliers or customers; market acceptance of the Company’s existing or new products may decrease; currency exchange rates may change unfavorably; pricing pressures from customers may increase; the macroeconomic environment may present adverse conditions; new products may not be feasible; work stoppages impacting the Company, its suppliers or customers, due to labor matters, civil or political unrest, infectious diseases and epidemics or other reasons, could harm the Company’s operations; free trade agreements may be altered or additional tariffs may be implemented; customers may not accept pass-through of tariff costs; the Company may be unable to protect its intellectual property in certain jurisdictions; there may be manufacturing or design defects or other quality issues with the Company’s products; the Company may be unable to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings; the Company’s business may be harmed by security breaches and other disruptions to its IT systems; the Company may be unable to comply with or may incur increased costs associated with complying with domestic and international regulations, which could change in an unfavorable manner; and other adverse conditions in the industries in which the Company operates may negatively affect its results.The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations,  acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results.Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. GENTHERM INCORPORATED CONSOLIDATED CONDENSED STATEMENTS OF (LOSS) INCOME (In thousands, except per share data) (Unaudited)  Three Months Ended  Six Months Ended  June 30,  June 30,  2020  2019  2020  2019 Product revenues$136,061  $243,326  $364,674  $501,247 Cost of sales 109,326   170,612   271,872   353,226 Gross margin 26,735   72,714   92,802   148,021 Operating expenses:               Net research and development expenses 15,341   19,255   33,101   38,152 Selling, general and administrative expenses 21,889   32,171   47,729   64,822 Restructuring expenses (598)  1,231   3,168   3,145 Total operating expenses 36,632   52,657   83,998   106,119 Operating (loss) income (9,897)  20,057   8,804   41,902 Interest expense, net (1,361)  (1,240)  (2,109)  (2,608 Foreign currency loss (1,741)  (804)  (2,679)  (601 Gain on sale of business —   —   —   4,970 Impairment loss —   (9,885)  —   (20,369 Other income 2,882   171   3,146   314 (Loss) earnings before income tax (10,117)  8,299   7,162   23,608 Income tax expense 205   5,548   5,611   12,443 Net (loss) income$(10,322) $2,751  $1,551  $11,165 Basic (loss) earnings per share$(0.32) $0.08  $0.05  $0.33 Diluted (loss) earnings per share$(0.32) $0.08  $0.05  $0.33 Weighted average number of shares – basic 32,580   33,441   32,635   33,508 Weighted average number of shares – diluted 32,580   33,574   32,869   33,651   GENTHERM INCORPORATED REVENUE BY PRODUCT CATEGORY (Unaudited, in thousands) Three Months Ended  Six Months Ended   June 30,  June 30,   2020 2019 % Change  2020 2019 % Change  Climate Control Seats (CCS)$49,879 $88,437 (43.6)% $132,407 $182,791 (27.6)% Seat Heaters 33,342  73,628 (54.7)%  97,874  147,548 (33.7)% Electronics 13,488  11,454 17.8%  23,864  24,306 (1.8)% Automotive Cables 9,833  22,205 (55.7)%  31,973  45,955 (30.4)% Steering Wheel Heaters 7,980  16,029 (50.2)%  27,215  32,999 (17.5)% Battery Thermal Management (BTM) 6,653  8,897 (25.2)%  17,862  19,641 (9.1)% Other Automotive 3,211  9,050 (64.5)%  9,663  18,817 (48.6)% Subtotal Automotive 124,386  229,700 (45.8)%  340,858  472,057 (27.8)% Medical 11,675  9,881 18.2%  23,816  18,068 31.8% GPT —  3,745 (100.0)%  —  7,704 (100.0)% CSZ-IC —  — 0.0%  —  3,418 (100.0)% Subtotal Industrial 11,675  13,626 (14.3)%  23,816  29,190 (18.4)% Total Company 136,061  243,326 (44.1)%  364,674  501,247 (27.2)%                    Total Core Businesses (Automotive and Medical)$136,061 $239,581 (43.2)% $364,674 $490,125 (25.6)% GENTHERM INCORPORATED RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA  (In thousands) (Unaudited) Three Months Ended Six Months Ended   June 30, June 30,   2020  2019 2020  2019  Net (loss) income$(10,322) $2,751 $1,551  $11,165  Add back:               Income tax expense 205   5,548  5,611   12,443  Interest expense 1,361   1,240  2,109   2,608  Depreciation and amortization 9,847   11,094  20,000   22,074  Adjustments:               Restructuring expense (598)  1,231  3,168   3,145  Impairment loss —   9,885  —   20,369  Gain on sale of business —   —  —   (4,970) Acquisition transaction expense —   342  —   380  Unrealized currency loss (gain) 1,609   71  2,374   (923) Gain on sale of patents (1,978)  —  (1,978)  —  CFO transition expenses —   —  —   1,065  Adjusted EBITDA$124  $32,162 $32,835  $67,356  Use of Non-GAAP Financial Measures In addition to the results reported in accordance with GAAP throughout this release, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company’s reconciliation of net income to Adjusted EBITDA is provided in this release. The Company’s Reconciliation of Adjusted EPS can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated August 4, 2020 and also is included in the presentation entitled “Q2 2020 Gentherm Incorporated Earnings Conference Presentation,” which can be found on the Events page of the Investor section of Gentherm's website at www.gentherm.com.In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.Non-GAAP measures referenced in this release may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.GENTHERM INCORPORATED ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS AND OTHER EFFECTS (In thousands, except per share data) (Unaudited) Three Months Ended  Six Months Ended   June 30,  June 30,   2020  2019  2020  2019  Transaction related current expenses                Acquisition transaction expenses$—  $342  $—  $380  Non-cash purchase accounting impacts                Customer relationships amortization 1,595   1,936   3,191   3,764  Technology amortization 438   498   877   980  Inventory fair value adjustment 108   117   216   156  Other effects                Restructuring expenses (598)  1,231   3,168   3,145  Gain on sale of business —   —   —   (4,970) Gain on sale of patents (1,978)  —   (1,978)  —  Impairment loss —   9,885   —   20,369  Unrealized currency (gain) loss 1,609   71   2,374   (923) CFO transition —   —   —   1,065  Total acquisition transaction expenses, purchase accounting   impacts and other effects$1,174  $14,080  $7,848  $23,966  Tax effect of above (619)  (1,117)  (2,329)  (905) Net income effect$555  $12,963  $5,519  $23,061                   Earnings per share - difference                Basic$0.02  $0.39  $0.17  $0.69  Diluted$0.02  $0.39  $0.17  $0.69   Adjusted earnings per share                Basic$(0.30) $0.47  $0.22  $1.02  Diluted$(0.30) $0.47  $0.22  $1.02  GENTHERM INCORPORATEDCONSOLIDATED CONDENSED BALANCE SHEETS (In thousands, except share data) (Unaudited) June 30, 2020  December 31, 2019  ASSETS        Current Assets:        Cash and cash equivalents$209,170  $50,443  Restricted cash 2,505   2,505  Accounts receivable, less allowance of $1,800 and $1,193, respectively 118,885   159,710  Inventory:        Raw materials 61,762   61,323  Work in process 6,575   7,444  Finished goods 44,293   49,712  Inventory, net 112,630   118,479  Other current assets 36,592   42,726  Total current assets 479,782   373,863  Property and equipment, net 149,240   160,605  Goodwill 64,629   64,572  Other intangible assets, net 48,399   49,783  Operating lease right-of-use assets 12,780   11,587  Deferred income tax assets 57,972   57,650  Other non-current assets 10,568   9,326  Total assets$823,370  $727,386  LIABILITIES AND SHAREHOLDERS’ EQUITY        Current Liabilities:        Accounts payable$65,521  $83,035  Current lease liabilities 4,184   4,586  Current maturities of long-term debt 2,500   2,500  Other current liabilities 63,805   66,583  Total current liabilities 136,010   156,704  Long-term debt, less current maturities 198,099   78,124  Pension benefit obligation 7,690   8,057  Non-current lease liabilities 10,097   6,751  Other non-current liabilities 2,153   5,100  Total liabilities$354,049  $254,736  Shareholders’ equity:        Common Stock:        No par value; 55,000,000 shares authorized 32,639,752 and 32,674,354 issued and outstanding at June 30, 2020 and December 31, 2019, respectively 104,113   102,507  Paid-in capital 9,770   10,852  Accumulated other comprehensive loss (47,845)  (42,441) Accumulated earnings 403,283   401,732  Total shareholders’ equity 469,321   472,650  Total liabilities and shareholders’ equity$823,370  $727,386  GENTHERM INCORPORATED CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS  (In thousands)  (Unaudited) Six Months Ended June 30,   2020  2019  Operating Activities:        Net income$1,551  $11,165  Adjustments to reconcile net income to net cash provided by operating activities:        Depreciation and amortization 20,488   22,217  Deferred income taxes (913)  3,070  Stock based compensation 3,909   3,291  Defined benefit plan income (278)  (699) Allowance for credit losses 605   545  Loss on sale of property and equipment 339   227  Operating lease expense 3,490   2,903  Impairment loss —   20,369  Gain on sale of business —   (4,970) Gain on sale of patents (1,978)  —  Changes in assets and liabilities:        Accounts receivable 37,805   (4,021) Inventory 5,292   1,650  Other assets 2,888   276  Accounts payable (17,753)  (9,528) Other liabilities (5,218)  (6,087) Net cash provided by operating activities 50,227   40,408  Investing Activities:        Purchases of property and equipment (7,500)  (13,024) Acquisition of intangible assets (3,141)  —  Proceeds from the sale of patents and property and equipment 1,061   82  Proceeds from divestiture of business —   47,500  Acquisition of subsidiary, net of cash acquired —   (15,476) Net cash (used in) provided by investing activities (9,580)  19,082  Financing Activities:        Borrowing of debt 201,193   28,371  Repayments of debt (81,830)  (61,120) Cash paid for financing costs —   (1,278) Cash paid for the cancellation of restricted stock (471)  (926) Proceeds from the exercise of Common Stock options 6,178   4,771  Cash paid for the repurchase of Common Stock (9,092)  (33,040) Net cash provided by (used in) financing activities 115,978   (63,222) Foreign currency effect 2,102   293  Net increase (decrease) in cash, cash equivalents and restricted cash 158,727   (3,439) Cash, cash equivalents and restricted cash at beginning of period 52,948   39,620  Cash, cash equivalents and restricted cash at end of period$211,675  $36,181  Supplemental disclosure of cash flow information:        Cash (refund) paid for taxes$(3,117) $3,522  Cash paid for interest$1,967  $2,712